Phase II Study of Intravesical Therapy With AD 32 in Patients With Papillary Urothelial Carcinoma or Carcinoma in Situ (CIS) Refractory to Prior Therapy With Bacillus Calmette-Guerin.
Phase of Trial: Phase II
Latest Information Update: 04 Jan 2019
At a glance
- Drugs Valrubicin (Primary)
- Indications Bladder cancer
- Focus Therapeutic Use
- 16 Jun 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 17 Sep 2005 New trial record.